ClinicalTrials.gg
Sign In

Burkitt Lymphoma clinical trials

The registry lists 976 studies for Burkitt Lymphoma across more than 10 countries. 159 are recruiting or about to start. 245 of them are mainly about Burkitt Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 983 studies for Burkitt Lymphoma. How that becomes 975 here

This page counts the studies the registry files under Burkitt Lymphoma, and those it files under no condition that list Burkitt Lymphomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 983Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1List Burkitt Lymphoma as a condition, but the registry did not file them under itMost often written as “AIDS-Related Burkitt Lymphoma” (1). The registry filed them under other conditions only, most often HIV Infections (1).
  3. −7Match it another way1 name it in the title, 1 in a keyword, and 5 by a synonym or other text the search reads.
  4. 975The count on this page

Get an email when these change. Save the Burkitt Lymphoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
509
Recruiting
128
Terminated
127
Status unknown
76
Active, not recruiting
52
Withdrawn
49

Phase

Phase 1
437
Phase 2
419
Phase 3
76
Early Phase 1
29
Phase 4
5

Where

United States
723
China
102
Canada
62
France
42
Italy
41
United Kingdom
36

Who runs them

National Cancer Institute (NCI) (112) · Fred Hutchinson Cancer Center (59) · M.D. Anderson Cancer Center (34) · City of Hope Medical Center (28) · Memorial Sloan Kettering Cancer Center (27) · Masonic Cancer Center, University of Minnesota (25) · Children's Oncology Group (24) · Case Comprehensive Cancer Center (22)

What is being tested here

Drugs under test in Burkitt Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Blinatumomab16835
Cyclophosphamide8886
Fludarabine6258
Inotuzumab Ozogamicin6317
Venetoclax6113
Etoposide4550
Prednisone4621
Doxorubicin4621
Dexamethasone3316
Ifosfamide3112

Drug classes tested here Antimetabolites 11 open · Alkylating agents 10 open · Corticosteroids 7 open · Antibody-drug conjugates (ADCs) 7 open · Tyrosine kinase inhibitors (TKIs) 4 open

Coming up

19phase 3 studies under way
60studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 128 Burkitt Lymphoma studies recruiting now, 38 (30%) set no upper age limit and 77 (60%) stop at 75 or younger. 75 (59%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (2%) take healthy volunteers.

Recruiting studies that take each age, of 128
AgeWomenMen
1054 (42%)54 (42%)
18124 (97%)124 (97%)
3099 (77%)99 (77%)
4088 (69%)88 (69%)
5087 (68%)87 (68%)
6583 (65%)83 (65%)
7565 (51%)65 (51%)
8547 (37%)47 (37%)

Across all 976 studies, recruiting or not: 42% stop at 75 or younger and 29% at 65; 46% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Burkitt Lymphoma studies take

Of 109 phase 1 interventional studies under Burkitt Lymphoma, half reached primary completion within 61 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 161 mo38–90 · 109 studies—57 mo38–90 · 87 studies
Phase 1/264 mo50–114 · 50 studies——
Phase 281 mo41–119 · 91 studies—83 mo42–120 · 83 studies
Phase 3106 mo78–119 · 19 studies——
Interventional, no phase96 mo50–144 · 20 studies——
Observational35 mo25–114 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Results posted1

Newly registered6

Show 1 more

Studies

Recruiting first, then most recently updated. Showing 50 of 976. Browse all 976 → or search them.